Drugs / Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells

Follow last change May 2021 re-read 9 days ago

Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells

targets CCR5 via inhibition

Developed for: HIV infectious disease
Investigated by: AIDS Malignancy Consortium · California Institute for Regenerative Medicine (CIRM) · National Cancer Institute (NCI)

today NCT02797470 · Ph 1/2

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02797470	Jun 2016 → May 2021 overdue	Burkitt lymphoma, HIV infectious disease, Hodgkins lymphoma, follicular lymphoma +3	AIDS Malignancy Consortium	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797470 ↗
Action	Inhibit	“prevent new immune cells from getting infected with HIV-1” NCT02797470 ↗
Route	Intravenous	“Patients undergo intravenous (IV) infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.” NCT02797470 ↗
Target	CCR5	“CCR5 shRNA” NCT02797470 ↗